Full-Time

Clinical Scientist

Posted on 1/8/2025

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Compensation Overview

$185k - $230kAnnually

+ Bonus + Equity Grant

Senior, Expert

San Carlos, CA, USA

The job is based in Redwood City, California, and there is no indication of remote work.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • Advanced degree (PhD or equivalent) in a relevant scientific field (e.g., Immunology, Cell Biology, Molecular Biology)
  • Proven experience (8+ years) in clinical development within the biopharmaceutical or biotechnology industry, preferably with exposure to cell therapy trials
  • Strong understanding of clinical trial design, implementation, and regulatory requirements
  • Proficiency in analyzing and interpreting clinical data, including statistical methods and data visualization techniques
  • Excellent communication skills with the ability to articulate complex scientific concepts to diverse stakeholders
  • Detail-oriented with a track record of delivering high-quality work under tight timelines
Responsibilities
  • Contribute to the development of clinical trial protocols and study materials
  • Collaborate with clinical operations, regulatory affairs, and other teams to ensure alignment on trial objectives and endpoints
  • Provide scientific input during site selection, investigator meetings, and trial initiation activities
  • Monitor trial progress and address scientific issues as they arise, ensuring adherence to protocol and regulatory requirements
  • Monitor clinical trial data for specific trends, develop data review plan in collaboration with data management, ensure CRF design supports data collection in alignment with the protocol
  • Analyze clinical trial data, generate study reports, and present findings to internal stakeholders
  • Contribute to the development of scientific publications and presentations based on trial results
  • Assist in preparing regulatory submissions, including IND/IMPD updates and responses to health authority inquiries
  • Stay informed of relevant regulatory guidelines and requirements to ensure trial compliance
  • Work closely with translational research, manufacturing, and quality teams to integrate scientific insights into trial operations
  • Collaborate with external partners, including contract research organizations (CROs) and academic institutions, as needed
  • Ensure trial data integrity and compliance with GCP (Good Clinical Practice) standards
  • Contribute to risk assessments and quality improvement initiatives

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary immunotherapy products and has a business model that includes research, development, and commercialization, generating revenue through partnerships and licensing agreements. The goal of Arcellx is to meet unmet medical needs by creating safe and effective treatment options.

Company Size

51-200

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Arcellx's partnership with Kite expands development in the blood cancer space.
  • The FDA's acceptance of CAR-T therapies boosts Arcellx's market potential.
  • Arcellx's innovative therapies address unmet medical needs in cancer treatment.

What critics are saying

  • Competition from Legend Biotech's Carvykti poses a threat to Arcellx's market share.
  • High costs of CAR-T therapies may limit patient accessibility and adoption.
  • Regulatory scrutiny could delay Arcellx's clinical trial timelines.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has Fast Track and Orphan Drug designations from the FDA.
  • The ARC-SparX platform offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced multiple myeloma cell targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Yahoo Finance
Mar 2nd, 2024
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.

PRWeek
Feb 7th, 2024
PR Week Global

Biotech Arcellx promotes Myesha Lacy to chief investor and comms officer | PR Week

INACTIVE